Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Top Cited Papers
- 1 August 2010
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 376 (9742) , 705-716
- https://doi.org/10.1016/s0140-6736(10)60934-8
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infectionHepatology, 2008
- Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological studyBMJ, 2008
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007
- SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 NonrespondersGastroenterology, 2007
- Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1Gastroenterology, 2006
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005